Stem Cell Injection Provides Pain Relief for Weeks

Article

Chronic pain is just one of many conditions that may be treated with an innovative stem cell-based therapy, according to researchers at Duke University.

Chronic pain is just one of many conditions that may be treated with an innovative stem cell-based therapy, according to researchers at Duke University.

Bone marrow stromal cells (BMSCs) are a type of stem cells that can provide healing effects and form into various other types of cells. With this understanding, Ru-Rong Ji, PhD, and colleagues examined how the stem cells could be used to alleviate neuropathic pain and other conditions. While previous research looked at BMSCs for pain relief, long-term effects were not examined.

The team studied mice with pain from nerve damage. They injected the BMSCs via lumbar puncture to the fluid surrounding the spinal cord.

“Based on these new results, we have the know-how and we can further engineer and improve the cells to maximize their beneficial effects,”Ji, a professor of anesthesiology and neurobiology in the Duke School of Medicine, said in a news release.

Patients with chronic pain have too little of the protein TGF-β1. According to the report posted in The Journal of Clinical Investigation, while evaluating the ways in which stem cells create analgesic effects the researchers found that higher concentrations of TGF-β1 were found in those treated with the injection. Chemically neutralizing the protein inhibited the pain relief of BMSCs. This suggests that TGF-β1 plays an important role in the soothing effects of stem cells.

The mice that were treated with BMSCs “were much less sensitive to painful stimuli,” the statement said. In addition, the stem cells connected with the nerve cells in the spinal cord.

“This analgesic effect was amazing. Normally, if you give an analgesic, you see pain relief for a few hours, at most a few days,” Ji explained.

With just one injection the team witnessed pain relief lasting for 4 to 5 weeks, although traces of BMSCs were found on site up to 3 months after the injection. Infusing just TGF-β1 into the spinal cord fluid was able to provide relief for a few hours.

Now that it has been determined that the protein is an intricate part of BMSCs analgesics, the team plans to find how to produce more of it. Pain caused by neuropathy, type 2 diabetes, chemotherapy, and other conditions may benefit from these findings.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.